SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 157884.
  • 2
    Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 158594.
  • 3
    Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195207.
  • 4
    Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 35577.
  • 5
    Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus 1999; 8: 47781.
  • 6
    Caramaschi P, Riccetti MM, Pasini AF, Savarin T, Biasi D, Todeschini G. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: report of three cases and review of the literature. Lupus 1998; 7: 3741.
  • 7
    Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999; 42: 234655.
  • 8
    Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28: 119.
  • 9
    Trent K, Neustater BR, Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Am J Hematol 1997; 54: 1559.
  • 10
    Umibe T, Nawata Y, Mori N, Kanai H, Takabayashi K, Iwamoto I, et al. Thrombotic thrombocytopenic purpura (TTP) observed in a patient with primary antiphospholipid antibody syndrome. Ryumachi 1994; 34: 9817.
  • 11
    Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol 1991; 18: 19168.
  • 12
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 13
    Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 18024.
  • 14
    Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82: 13825.
  • 15
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 176572.
  • 16
    Kay AC, Solberg LA Jr, Nichols DA, Petitt RM. Prognostic significance of computed tomography of the brain in thrombotic thrombocytopenic purpura. Mayo Clin Proc 1991; 66: 6027.
  • 17
    Bakshi R, Shaikh ZA, Bates VE, Kinkel PR. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients. Neurology 1999; 52: 12858.
  • 18
    Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 18426.
  • 19
    Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol 2001; 112: 10878.
  • 20
    Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 27305.
  • 21
    Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 7103.
  • 22
    Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 608.
  • 23
    Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88: 9148.
  • 24
    Montecucco C, Di Lauro M, Bobbio-Pallavicini E, Longhi M, Caporali R, De Gennaro F, et al. Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol 1987; 5: 3558.